HC Wainwright Lowers Earnings Estimates for Delcath Systems

Delcath Systems, Inc. (NASDAQ:DCTH) – Analysts at HC Wainwright cut their Q1 2026 earnings per share estimates for Delcath Systems in a research note issued on Monday, March 2nd. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.01) per share for the quarter, down from their prior estimate of $0.13. HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Delcath Systems’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Delcath Systems’ Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.27) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at $0.10 EPS and FY2028 earnings at $1.13 EPS.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. The company had revenue of $20.73 million for the quarter, compared to the consensus estimate of $20.35 million. Delcath Systems had a return on equity of 2.70% and a net margin of 3.17%.

DCTH has been the topic of a number of other reports. Stephens reduced their price target on shares of Delcath Systems from $25.00 to $18.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. BTIG Research cut their target price on shares of Delcath Systems from $23.00 to $19.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Weiss Ratings restated a “sell (d+)” rating on shares of Delcath Systems in a report on Monday, December 29th. Evercore set a $27.00 price target on shares of Delcath Systems in a research report on Thursday, February 26th. Finally, Wall Street Zen lowered Delcath Systems from a “buy” rating to a “hold” rating in a research report on Saturday. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Delcath Systems Stock Performance

Shares of NASDAQ:DCTH opened at $8.60 on Wednesday. The stock has a 50-day simple moving average of $9.93 and a 200-day simple moving average of $10.17. The stock has a market capitalization of $298.85 million, a P/E ratio of 122.86 and a beta of 0.38. Delcath Systems has a 1 year low of $8.12 and a 1 year high of $18.23.

Delcath Systems announced that its board has initiated a stock repurchase program on Thursday, November 20th that allows the company to buyback $25.00 million in outstanding shares. This buyback authorization allows the company to repurchase up to 8.6% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s leadership believes its shares are undervalued.

Institutional Investors Weigh In On Delcath Systems

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System purchased a new position in Delcath Systems in the 2nd quarter valued at about $26,000. Russell Investments Group Ltd. acquired a new position in shares of Delcath Systems in the third quarter worth about $29,000. Tower Research Capital LLC TRC acquired a new position in shares of Delcath Systems in the second quarter worth about $40,000. Ameritas Investment Partners Inc. purchased a new position in Delcath Systems in the second quarter valued at about $42,000. Finally, Legal & General Group Plc acquired a new stake in Delcath Systems during the 2nd quarter valued at approximately $46,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Key Stories Impacting Delcath Systems

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Publication of full CHOPIN randomized Phase 2 clinical trial results in The Lancet Oncology supports Delcath’s clinical credibility and could help commercial adoption and future partnerships or trials. CHOPIN Clinical Trial Publication
• Neutral Sentiment: Analyst coverage remains constructive on the long horizon: HC Wainwright keeps a “Buy” rating and a $30 price target, and also published bullish FY2029–FY2030 EPS projections (showing material upside several years out), which supports a positive long‑term thesis even as near‑term estimates were cut. MarketBeat DCTH Coverage
• Neutral Sentiment: Coverage piece argues fundamentals remain intact despite recent share weakness and notes near‑term pressure from patient starts and planned investments; useful context for investors weighing operational vs. sentiment drivers. Seeking Alpha Article
• Neutral Sentiment: Reported short interest data is unreliable/malformed in the filings (shows zeros/NaN); nothing actionable from the published short‑interest numbers as provided.
• Negative Sentiment: HC Wainwright sharply cut near‑term and medium‑term EPS estimates across Q1–Q4 2026 and FY2026–FY2028 (examples: FY2026 to ($0.86) from $0.58; FY2027 to $0.10 from $1.25; FY2028 to $1.13 from $1.77), signaling weaker near‑term profitability expectations and higher execution risk — a likely driver of today’s downward pressure on the share price. HC Wainwright Estimate Revisions

About Delcath Systems

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.